NFIL3 protein identified as key driver of CAR T-cell exhaustion in animal models
Disabling the transcription factor NFIL3 in engineered CAR T cells prolonged their anti-tumour activity in mouse models, according to new research reported by ScienceDaily.
Researchers have identified NFIL3, a transcription factor, as a significant contributor to the functional exhaustion of CAR T cells — the engineered immune cells used in certain blood-cancer therapies. The study, reported via ScienceDaily on 2 June 2026, found that NFIL3 activity causes CAR T cells to lose their cancer-fighting capacity over time, a problem that has limited the durability of responses in patients treated with these therapies.
When the researchers disabled NFIL3 in CAR T cells, the cells maintained stronger effector function for longer and demonstrated improved tumour control in animal models. The work adds a named molecular target to an area of active investigation: how to prevent the exhaustion phenotype that reduces CAR T-cell efficacy after initial response.
The primary research paper and the institution responsible for the work were not specified in the available reporting. The findings are from animal models, and the relationship between these preclinical observations and outcomes in human disease remains to be established through further research. No peer-reviewed publication details were available in the feed item at time of writing.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
CAR T-cell therapy is a type of cancer treatment in which a patient's own immune cells are taken out, genetically modified in a laboratory to help them find and attack cancer cells, and then returned to the body. One problem with this approach is that the modified cells can become 'exhausted' — meaning they lose the ability to keep fighting cancer over time.
Researchers have found that a protein called NFIL3 appears to play a major role in causing this exhaustion. When they switched off NFIL3 in laboratory experiments using mice, the modified cells stayed active for longer and did a better job of controlling tumours. This research is still at the animal-study stage, which means it is not yet known whether the same will apply in people.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source ScienceDaily · 2026-06-02A single protein may be holding back CAR T cancer therapy